Xiao-Li Mai

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The effect of mesenchymal stem cell (MSCs)-based therapy on treating acute myocardial infarction (MI) is limited due to poor engraftment and limited regenerative potential. Here we engineered MSCs with integrin-linked kinase (ILK), a pleiotropic protein critically regulating cell survival, proliferation, differentiation, and angiogenesis. We firstly(More)
  • 1